Atlas Trials

TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Clinical trial NCT03503968 · TERMINATED

Trial details

NCT number
NCT03503968
Sponsor
Medigene AG
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
SafetyTolerabilityFeasibilityTreatment Efficacy
Start date
2018-03-27
Primary completion
2022-06-28
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.